A Nucleic Acid Drug, TRK-250, Receives Orphan Drug Designation*1 from ...
TRK-250 is a nucleic acid medicine that inhibits the progression of pulmonary fibrosis by selectively suppressing the expression of transforming growth factor-beta 1 (TGF-β1) protein, …
TRK-250 | Pulmonary Fibrosis Foundation
TRK-250 is a nucleic acid medicine that inhibits the progression of pulmonary fibrosis by selectively suppressing the expression of transforming growth factor-beta 1 (TGF-β1) protein, …
A Novel siRNA-Based Oligonucleotide, TRK-250, and Its Efficacy …
A Novel siRNA-Based Oligonucleotide, TRK-250, and Its Efficacy for Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Trials and Treatments: An Update on Pharmacotherapy for …
TRK 250, previously known as BNC 1021, is a novel agent that consists of a single stranded oligonucleotide capable of producing silencing RNA (siRNA) targeting TGF-β1 mRNA.
A Phase I Study of TRK-250, a Novel siRNA-Based ... - PubMed
Purpose: TRK-250 is a novel single-stranded oligonucleotide carrying a human Transforming growth factor-beta 1-targeting siRNA motif tethered by two proline linkers. Nonclinical studies …
A Study to Evaluate the Safety, Tolerability, and ... - Mayo Clinic
TRK-250 is a nucleic acid medicine that inhibits the progression of pulmonary fibrosis by selectively suppressing the expression of transforming growth factor-beta 1 (TGF-β1) protein, …
Toray Announces Initiation of Phase 1 Clinical Trial of TRK-250 for ...
TRK-250/BNC-1021 is a nucleic acid medicine that inhibits the progression of pulmonary fibrosis by selectively suppressing the expression of transforming growth factor-beta 1 (TGF-β1) …
A Phase I Study of TRK-250, a Novel siRNA-Based …
Dec 12, 2023 · Purpose: TRK-250 is a novel single-stranded oligonucleotide carrying a human Transforming growth factor-beta 1-targeting siRNA motif tethered by two proline linkers. …
- [PDF]
2023;207:A4823
TRK-250 is a novel class of single-stranded oligonucleotide carrying a human TGF-β1-targeting siRNA motif tethered by two proline linkers. Nonclinical studies have demonstrated that TRK …
TRK-250: Uses, Interactions, Mechanism of Action | DrugBank Online
Sep 27, 2023 · TRK-250 is a small interfering RNA agent that targets human transforming growth factor-beta 1 (TGF-β1) messenger RNA.